Vijaya Juturu Ph.D., F.A.C.N., Senior Manager of Global Scientific and Clinical Affairs, OmniActive Health Technologies Inc. will present findings from the study “Salacia Extract Improves Post-Prandial Glucose and Insulin Response: A Randomized Double-Blind, Placebo-Controlled, Crossover Study in Healthy Volunteers” at the Experimental Biology Conference, April 2-6 in San Diego, Calif. (USA). The randomized, placebo-controlled, double-blind trial was performed on normal, healthy individuals.

“Our purpose was to evaluate the acute effect of Salacia extract, an alpha-glucosidase inhibitor, on glucose and insulin response (to an oral sucrose load) in healthy individuals,” stated Dr. Jayant Deshpande, CTO of OmniActive Health Technologies. “Through its ability to inhibit alpha-glucosidase enzyme, SE shows tremendous potential to support healthy blood glucose and insulin levels by decreasing carbohydrate absorption.”
OmniLean Salacia Extract experienced a successful market launch earlier this month at Engredea/Natural Products Expo 2016 at Anaheim, Calif (USA).

“OmniLean is a scientifically validated ingredient that represents a new class of ingredients from OmniActive which we call ‘metabolic synergizers’,” said Lynda Doyle, VP of Global Marketing, OmniActive Health Technologies. “OmniLean is truly a unique ingredient for metabolic health, and there has been strong interest since its introduction to the market.”

OmniLean provides a comprehensive approach to achieving multiple objectives of healthy metabolism including healthy carbohydrate metabolism, fat metabolism, heart health and weight management in one convenient, low dose ingredient from a traceable, reliable supply chain. OmniActive’s unique PlantActive™ veri?cation process standardizes both bioactives and bioactivity to ensure consistent performance of OmniLean. OmniLean is a free-?owing powder for a variety of applications including tablets, capsules and powders – e.g. meal replacements, protein, etc.